Clinical and Experimental Vaccine Research

  • 제12권2호
  • /
  • Pages.121-126
  • /
  • 2023
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

Nondaily dosing schedule of allergen-specific sublingual immunotherapy: efficacy and safety

  • Heba Wagih Abdelwahab (Department of Chest Medicine, Mansoura University) ;
  • Amina Abd El-Maksoud (Department of Chest Medicine, Mansoura University)
  • 투고 : 2022.09.23
  • 심사 : 2023.02.05
  • 발행 : 2023.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Sublingual immunotherapy is currently promoted by various companies, with administration schedules variable in the different products even though almost all are standardized immunologically. So, this study was planned to examine the efficacy of simple nondaily dosing of sublingual immunotherapy instead of the widely used daily schedule. Materials and Methods: Fifty-two patients with allergic rhinitis and bronchial asthma were enrolled. Sublingual immunotherapy (manufactured at the allergen immunotherapy preparation unit at Mansoura University) was given in suitable bottles with a dropper mechanism that permits comfortable dosing under the tongue. The physician recommended that the patient put the drops under his/her tongue and leave the drops beneath the tongue for 2 minutes before swallowing. This was repeated every 3 days, with the drop number and concentration gradually rising. Results: After 2 months of follow-up, 65.8% responded partially to the symptom score and 26.3% responded completely to the medication score. There was a significant decline in the symptom and medication scores from the baseline scores (p<0.0001). After 4 months of follow-up, 95.8% responded partially to symptom scores and no one has not responded; 54.2% responded completely to medication scores; and 81% of studied patients had no side effects. However, the most frequent side effect was a sore throat. Conclusion: Our nondaily schedule of sublingual immunotherapy is tolerable, safe, and effective in patients with allergic rhinitis and bronchial asthma.

키워드

과제정보

The authors extend their thanks and appreciation to all the allergen immunotherapy lab members (Chest Medicine Department, Mansoura University, especially Mr. Hesham Al-Minshawi, lab specialist).

참고문헌

  1. Mosges R, Breitruck NY, Allekotte S, et al. Shortened updosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season. World Allergy Organ J 2019;12:100012.
  2. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64 Suppl 91:1-59.
  3. Palomares O, Ruckert B, Jartti T, et al. Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol 2012;129:510-20.
  4. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6.
  5. Kawauchi H, Goda K, Tongu M, et al. Short review on sublingual immunotherapy for patients with allergic rhinitis: from bench to bedside. Adv Otorhinolaryngol 2011;72:103-6.
  6. Demoly P, Passalacqua G, Calderon MA, Yalaoui T. Choosing the optimal dose in sublingual immunotherapy: rationale for the 300 index of reactivity dose. Clin Transl Allergy 2015;5:44.
  7. GINA Science Committee. Global strategy for asthma management and prevention 2021 [Internet]. Fontana (WI): Global Initiative for Asthma; 2021 [cited 2022 Mar 20]. Available from: https://ginasthma.org/
  8. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63 Suppl 86:8-160.
  9. Heinzerling L, Mari A, Bergmann KC, et al. The skin prick test: European standards. Clin Transl Allergy 2013;3:3.
  10. Abdelwahab HW, El-Maksoud AA, Farrag NS, Fouda AM, Ehab A. Association of allergen sensitization patterns with clinical outcome of subcutaneous allergen-specific immunotherapy in polysensitized allergic patients. Egypt J Chest Dis Tuberc 2022;71:388-94.
  11. Abu El-Enin MA, Rabie Shehab El-Din EM, Abdelwahab HW, et al. Preparation of chemically stable allergen-specific sublingual immunotherapy from Egyptian allergens. J Clin Lab Anal 2022;36:e24261.
  12. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010;40:922-32.
  13. Demoly P, Calderon MA. Dosing and efficacy in specific immunotherapy. Allergy 2011;66 Suppl 95:38-40.
  14. Calderon MA, Larenas D, Kleine-Tebbe J, et al. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'. Allergy 2011;66:1345-59.
  15. Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014;133:1608-14.
  16. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45.
  17. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:1394-401.
  18. Wang L, Yin J, Fadel R, Montagut A, de Beaumont O, Devillier P. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 2014;69:1181-8.
  19. Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol 2013;13:656-62.
  20. Demoly P, Calderon MA, Casale TB, Malling HJ, Wahn U. "The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis". Clin Transl Allergy 2015;5:18.
  21. Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. London: European Medicines Agency; 2008.
  22. Tripathi DM, Joshi SV, Dhar HL. Efficacy of sublingual immunotherapy with multiple allergens in bronchial asthma. Bombay Hosp J 2008;50:227-31.
  23. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 2006;97:126-37.
  24. Bernstein DI, Epstein T. Systemic reactions to subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am 2011;31:241-9.
  25. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005;116:109-18.
  26. Moreno C, Fernandez-Tavora L, Acero S, et al. Tolerance of a cluster schedule on the treatment of seasonal allergic respiratory disease with pollen extracts quantified in mass units. J Investig Allergol Clin Immunol 2003;13:221-7.
  27. Frati F, La Grutta S, Bernardini R, et al. Sublingual immunotherapy: administration, dosages, use. Int J Immunopathol Pharmacol 2009;22(4 Suppl):13-6.